Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Gliosarcoma × encorafenib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Melanoma 16 Colorectal Neoplasms 9 Brain Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Neoplasms 3 Colonic Neoplasms 3 Lung Neoplasms 2 Thyroid Neoplasms 1 Skin Neoplasms 1 Recurrence 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Multiple Myeloma 1 Lymphatic Metastasis 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Gliosarcoma 1 Glioma 1 Glioblastoma 1 Astrocytoma 1

Interventions

Temozolomide 42 Radiotherapy 33 Bevacizumab 30 Carmustine 12 Irinotecan 10 Erlotinib Hydrochloride 10 sargramostim 7 Thalidomide 7 Chemotherapy, Adjuvant 7 Carboplatin 6 pembrolizumab 5 Radiation 5 Magnetic Resonance Spectroscopy 5 Cyclophosphamide 5 Topotecan 4 Surgical Procedures, Operative 4 Drug Therapy 4 Celecoxib 4 cediranib 3 aldesleukin 3 Tamoxifen 3 Radiotherapy, Intensity-Modulated 3 Radiotherapy, Conformal 3 O(6)-benzylguanine 3 Gefitinib 3 Filgrastim 3 FANG vaccine 3 Bortezomib 3 Aminolevulinic Acid 3 pazopanib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03973918 2024-10-31

BRAF

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Terminated

5 enrolled 15 charts

Astrocytoma, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡